Literature DB >> 33597718

Neurotrophin receptor activation rescues cognitive and synaptic abnormalities caused by hemizygosity of the psychiatric risk gene Cacna1c.

Cezar M Tigaret1, Tzu-Ching E Lin1, Edward R Morrell2,3, Lucy Sykes1,4, Anna L Moon1,5, Michael C O'Donovan1,5, Michael J Owen1,5, Lawrence S Wilkinson1,2,5, Matthew W Jones3, Kerrie L Thomas1,6, Jeremy Hall7,8.   

Abstract

Genetic variation in CACNA1C, which encodes the alpha-1 subunit of CaV1.2 L-type voltage-gated calcium channels, is strongly linked to risk for psychiatric disorders including schizophrenia and bipolar disorder. To translate genetics to neurobiological mechanisms and rational therapeutic targets, we investigated the impact of mutations of one copy of Cacna1c on rat cognitive, synaptic and circuit phenotypes implicated by patient studies. We show that rats hemizygous for Cacna1c harbour marked impairments in learning to disregard non-salient stimuli, a behavioural change previously associated with psychosis. This behavioural deficit is accompanied by dys-coordinated network oscillations during learning, pathway-selective disruption of hippocampal synaptic plasticity, attenuated Ca2+ signalling in dendritic spines and decreased signalling through the Extracellular-signal Regulated Kinase (ERK) pathway. Activation of the ERK pathway by a small-molecule agonist of TrkB/TrkC neurotrophin receptors rescued both behavioural and synaptic plasticity deficits in Cacna1c+/- rats. These results map a route through which genetic variation in CACNA1C can disrupt experience-dependent synaptic signalling and circuit activity, culminating in cognitive alterations associated with psychiatric disorders. Our findings highlight targeted activation of neurotrophin signalling pathways with BDNF mimetic drugs as a genetically informed therapeutic approach for rescuing behavioural abnormalities in psychiatric disorder.
© 2021. The Author(s).

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 33597718      PMCID: PMC8440217          DOI: 10.1038/s41380-020-01001-0

Source DB:  PubMed          Journal:  Mol Psychiatry        ISSN: 1359-4184            Impact factor:   13.437


Introduction

The major psychiatric disorders such as schizophrenia and bipolar disorder place an enormous burden on society yet have seen little advances in mechanistic understanding and therapy. While schizophrenia and bipolar disorder can present differently in the clinic, both are associated with psychosis and they have significantly shared genetic architecture [1]. Recent advances in the understanding of the genomic basis of these conditions may pave the way to new therapeutics [2]. Particularly promising in this respect is the demonstration of strong associations of both schizophrenia and bipolar disorder with genetic variations in voltage-gated calcium channels (VGCCs) [3], especially the CACNA1C gene, which encodes the pore-forming α1C subunit of CaV1.2 L-type VGCCs (L-VGCCs) [4, 5]. The exact molecular effects of the CACNA1C risk-associated single nucleotide polymorphisms (SNPs) are not fully understood. Common risk SNPs in CACNA1C are intronic and likely to alter CACNA1C gene expression, with decreased expression seen in some, but not all, studies [6-10]. Recent evidence suggests that in human hippocampus the risk SNPs act to reduce CACNA1C expression [10]. The association of rare deleterious mutations in genes encoding VGCC subunits, including CACNA1C, with schizophrenia and other neurodevelopmental disorders further supports the view that decreased CACNA1C expression can contribute to disease risk [11, 12]. Understanding the functional effects of CACNA1C dosage, and in particular reduced dosage, is therefore necessary to discerning the contribution of genetic variation in L-VGCCs to neuropsychiatric risk. CaV1.2 L-VGCCs are highly expressed in the mammalian brain, including hippocampus [13]. Clinical and preclinical studies implicate hippocampal abnormalities in the pathophysiology of schizophrenia and bipolar disorder [14-16], and impaired hippocampus-dependent associative learning in the development of psychosis [17-20]. Hippocampal associative learning is orchestrated by rhythmic neural activity in the entorhinal-hippocampal network [21, 22] and is underpinned by associative synaptic plasticity at glutamatergic synapses, induced by coordinated activation of postsynaptic NMDA receptors (NMDAR) and VGCCs including L-VGCCs [23-26]. At a molecular level L-VGCCs link membrane depolarization to transcription via the Extracellular-signal Regulated Kinase (ERK) signalling pathway which regulates synaptic plasticity [27-30] and activates transcription factors including CREB controlling the expression of genes required for long-term plasticity [29, 30]. Thus, L-VGCC-mediated calcium signalling regulates the changes in synaptic efficacy and gene expression underlying associative learning. In this study we used a Cacna1c rat model [31] in order to examine the impact of reduced Cacna1c dosage on hippocampal associative learning, synaptic plasticity, circuit activity and ERK signalling. Having mapped the mechanistic links between genetic variation in Cacna1c and behavioural phenotype we showed that activation of ERK signalling with a small-molecule TrkB/TrkC neurotrophin receptor agonist could rescue the behavioural and synaptic plasticity impairments.

Materials and methods

Animals

Cacna1c rats [31] with a truncating mutation in exon 6 of Cacna1c gene were generated from cryo-preserved embryos (strain SD-Cacna1c, Sage Research Labs, Pennsylvania, USA) and bred at Charles River (Margate, UK), Cardiff and Bristol Universities. We used 278 Cacna1c and heterozygous littermates, and 54 male Lister Hooded rats (Charles River, UK) for behavioural experiments using intrahippocampal diltiazem (DTZ) infusion. Littermates were housed up to four per cage, with access to food and water ad libitum. Experiments were performed on mature animals (age: 12–52 weeks) [32] maintained under normal (12 h/12 h) or reversed light/dark cycle (dark: 10 a.m. to 8 p.m. for behavioural studies; behavioural training at 11 a.m.). Animal handling followed Home Office regulations as directed by Home Office Licensing teams at the host institutions.

Behavioural, electrophysiological, and molecular methods

These procedures are described in Supplementary Materials and methods.

Statistical analysis

Sample sizes were determined as described in Supplementary Materials. Animals were assigned pseudo-randomly to experimental groups, with experiments performed blind to genotype. Specific statistical analyses are given in Supplementary Materials and methods. Pooled data are represented as mean ± SEM. Asterisks show statistical significance: *p < 0.05; **p < 0.01; ***p < 0.001.

Results

Cacna1c hemizygosity disrupts latent inhibition of contextual fear conditioning

We investigated the effects of reduced CaV1.2 dosage on associative fear learning using rats hemizygous for a truncating mutation in exon 6 of Cacna1c gene encoding the pore-forming α1C subunit of CaV1.2 L-VGCCs [33] (“Materials and methods”). Cacna1c+/− rats have an approximately 50% decrease in hippocampal Cacna1c mRNA and protein [31]. We assessed the behavioural impact of Cacna1c hemizygosity by testing contextual fear conditioning (CFC) in Cacna1c and wild-type littermates, a hippocampal-dependent behavioural response that requires L-VGCC activation [34, 35]. During training animals received a single mild footshock (US, 2 s, 0.5 mA) 2 min after being placed in a novel context (Fig. 1A and Supplementary Methods). Context-fear association memory was assessed by measuring the freezing response upon return to the conditioned context 3 h (short-term memory, STM), 24 h (long-term memory, LTM1), and 8 days (LTM2) after CFC training. Cacna1c and Cacna1c animals had equivalent levels of fear response throughout training and recall sessions (Figs. 1A and S1), indicating that reduced dosage of Cacna1c did not alter contextual fear learning per se.
Fig. 1

Low Cacna1c dosage selectively impairs latent inhibition (LI) of contextual fear memory CFM.

All panels: Left: schematics of behavioural protocols (top) and freezing responses measured during all trials (bottom). PE: 4 h context pre-exposure; CFC contextual fear conditioning comprising Pre-US and Post-US epochs before and after footshock (US), respectively; STM, LTM1, LTM2: short-term and long-term contextual fear memory (CFM) retrieval trials. Right: Summary of freezing responses at LTM tests. A Acquisition and consolidation of CFC are unaltered in Cacna1c animals. Effects of genotype: F(1,12) = 0.385, p = 0.546, trial: F(4,48) = 29.624, p < 0.001; genotype × trial interaction: F(4,48) = 0.533, p = 0.712; Cacna1c: n = 6; Cacna1c: n = 8. B Higher levels of freezing post-US and during CFM retrieval trials indicate the Cacna1c animals have a deficit in the LI. Genotype × session interaction: F(2.1,31.49) = 6.119, p = 0.005; pairwise comparisons between genotypes: Post-US: F(2.1,31.47) = 10.464, p = 0.006; LTM1: F(2.1,31.49) = 8.895, p = 0.009; LTM2: F(2.1,31.49) = 9.869, p = 0.007 (Greenhouse–Geisser corrected); Cacna1c: n = 9; Cacna1c: n = 8. Data presented as means ± SEM. **p < 0.01 determined by two-way repeated measures ANOVA followed by pairwise post-hoc comparison with Bonferroni correction.

Low Cacna1c dosage selectively impairs latent inhibition (LI) of contextual fear memory CFM.

All panels: Left: schematics of behavioural protocols (top) and freezing responses measured during all trials (bottom). PE: 4 h context pre-exposure; CFC contextual fear conditioning comprising Pre-US and Post-US epochs before and after footshock (US), respectively; STM, LTM1, LTM2: short-term and long-term contextual fear memory (CFM) retrieval trials. Right: Summary of freezing responses at LTM tests. A Acquisition and consolidation of CFC are unaltered in Cacna1c animals. Effects of genotype: F(1,12) = 0.385, p = 0.546, trial: F(4,48) = 29.624, p < 0.001; genotype × trial interaction: F(4,48) = 0.533, p = 0.712; Cacna1c: n = 6; Cacna1c: n = 8. B Higher levels of freezing post-US and during CFM retrieval trials indicate the Cacna1c animals have a deficit in the LI. Genotype × session interaction: F(2.1,31.49) = 6.119, p = 0.005; pairwise comparisons between genotypes: Post-US: F(2.1,31.47) = 10.464, p = 0.006; LTM1: F(2.1,31.49) = 8.895, p = 0.009; LTM2: F(2.1,31.49) = 9.869, p = 0.007 (Greenhouse–Geisser corrected); Cacna1c: n = 9; Cacna1c: n = 8. Data presented as means ± SEM. **p < 0.01 determined by two-way repeated measures ANOVA followed by pairwise post-hoc comparison with Bonferroni correction. We next assessed the performance of Cacna1c and Cacna1c littermates in a paradigm of latent inhibition (LI) of CFC (schematics in Figs. 1B, S1A). LI is the reduced ability to form conditioned associations to a stimulus (here, the conditioning context) due to pre-exposure to stimulus alone and reflects learning to ignore irrelevant stimuli, which is impaired in psychosis [17, 18, 36]. Animals were pre-exposed to the to-be-conditioned context (PE) for 4 h, then trained for CFC 24 h or 48 h later (Figs. 1B, S1). Pre-exposure produced a robust LI of CFC in Cacna1c animals, manifested as reduced freezing response at LTM trials, but not in Cacna1c littermates (Figs. 1B, S1 comparing pre-exposed and non-pre-exposed animals). Therefore, Cacna1c hemizygosity selectively impaired LI of CFC. In wild-type animals LI of CFC was disrupted by infusion of L-VGCC antagonist DTZ in dorsal hippocampus during pre-exposure (Fig. S2). Together, these results demonstrate a specific role for hippocampal CaV1.2 channels during the pre-exposure stage in LI of CFC paradigm. We therefore focussed our further physiological studies on the hippocampus. LI of CFC requires dorsal hippocampal-dependent formation of context-specific memories [37]. We hypothesized that the LI of CFC deficit in Cacna1c animals reflects a disruption of dorsal hippocampal processes that encode novel environment representations during pre-exposure. Therefore, we investigated the impact of Cacna1c hemizygosity on two fundamental hippocampal mechanisms proposed to support memory encoding: associative plasticity at CA1 pyramidal cell synapses [23] and phase–amplitude coupling (PAC) between the theta and gamma oscillations of the local field potential (LFP) in CA1 [21].

Cacna1c rats have disrupted synaptic plasticity in dorsal hippocampal CA1

Formation of stable hippocampal context-specific representations requires strengthening of cortical excitatory inputs to CA1 pyramidal neurons via Schaffer collaterals (SC-CA1) from the CA3 area and the temporo-ammonic (TA-CA1) pathway [38-41]. We examined the induction of synaptic long-term potentiation (LTP) at SC-CA1 and TA-CA1 synapses in ex vivo dorsal hippocampal slices from Cacna1c+/− and Cacna1c+/+ rats. We initially used a theta-burst pairing protocol (TBP) consisting of synaptic stimulation coincident with postsynaptic action potentials (APs) (Fig. 2A). TBP mimics theta-burst firing patterns observed in vivo during learning and exploration of novel environments [40, 42, 43] and induces LTP (TBP-LTP) through coordinated activation of postsynaptic NMDAR and VGCCs [26, 44]. TBP failed to induce SC-CA1 LTP in Cacna1c+/− animals (Fig. 2B, D). This deficit was present in male and female Cacna1c animals (Fig. S3), therefore subsequent experiments were performed in males. In Cacna1c+/+ slices TBP produced robust SC-CA1 LTP (Fig. 2C, D) which was blocked by L-VGCC antagonists isradipine, DTZ, and the NMDAR antagonist L-689560 (Fig. S4A–C, H), confirming NMDAR and L-VGCC requirements for TBP-LTP.
Fig. 2

Reduced Cacna1c dosage impairs LTCC-sensitive induction of associative LTP selectively at Schaffer collateral to CA1 (SC-CA1) synapses.

A Electrodes placements (left) and theta-burst pairing (TBP) protocol (right) for LTP at SC-CA1 synapses. B No TBP-induced LTP at SC-CA1 synapses in Cacna1c+/− slices. C TBP-induced robust homosynaptic LTP at SC-CA1 in Cacna1c+/+ slices. D Summary of normalized change in EPSC amplitude at 30–35 min shown in (B) and (C). Effect of genotype on LTP: LR(1) = 5.16, p = 0.023; genotype × pathway interaction: LR(1) = 7, p = 0.0081. Pairwise comparisons of Test vs Control pathway for Cacna1c: p = 0.99, n = 17 (12: 4 females and 8 males); Cacna1c: p = 0.0057, n = 16(9). E Electrodes placements (left) and low-frequency stimulation (LFS-pairing) protocol (right) for SC-CA1 LTP. LFS-pairing induces SC-CA1 LTP in Cacna1c (F) and Cacna1c+/+ slices (G). H Summary of EPSC amplitude change at 30–35 min shown in (F) and (G): no effect of genotype (LR(1) = 0.103, p = 0.748) or genotype × pathway interaction (LR(1) = 0.227, p = 0.633) on LTP. Pairwise Test vs Control for Cacna1c+/−: p = 0.0027, n = 10(7); Cacna1c+/+: p = 0.0011, n = 8(6). I Electrode placements (left) and TBP protocol (right) for LTP at TA-CA1 synapses. TBP induces homosynaptic TA-CA1 LTP in slices from Cacna1c (J) and Cacna1c animals (K). L Summary of changes in normalized EPSC amplitude at 30–35 min shown in (F) and (G): no effect of genotype (LR(1) = 0.0258, p = 0.8724) and no genotype × pathway interaction (LR(1) = 0.065, p = 0.798); contrast Test versus Control pathways, in Cacna1c: p = 0.0093, n = 8(7); Cacna1c: p = 0.014, n = 7(5). Plots show EPSC amplitude time-course in Test and Control pathways, normalized to 5 min average before LTP induction (arrowheads). Insets: 5 min average EPSC waveforms before (1, black) and 30–35 min after (2, red) LTP induction; scale bars: 50 pA, 50 ms. Sample sizes given as cells(animals—all males unless indicated). Data presented as means ± SEM. *p < 0.05, **p < 0.01 determined by two-way ordinal regression (cumulative link model) followed by analysis of deviance (ANODE) (colour figure online).

Reduced Cacna1c dosage impairs LTCC-sensitive induction of associative LTP selectively at Schaffer collateral to CA1 (SC-CA1) synapses.

A Electrodes placements (left) and theta-burst pairing (TBP) protocol (right) for LTP at SC-CA1 synapses. B No TBP-induced LTP at SC-CA1 synapses in Cacna1c+/− slices. C TBP-induced robust homosynaptic LTP at SC-CA1 in Cacna1c+/+ slices. D Summary of normalized change in EPSC amplitude at 30–35 min shown in (B) and (C). Effect of genotype on LTP: LR(1) = 5.16, p = 0.023; genotype × pathway interaction: LR(1) = 7, p = 0.0081. Pairwise comparisons of Test vs Control pathway for Cacna1c: p = 0.99, n = 17 (12: 4 females and 8 males); Cacna1c: p = 0.0057, n = 16(9). E Electrodes placements (left) and low-frequency stimulation (LFS-pairing) protocol (right) for SC-CA1 LTP. LFS-pairing induces SC-CA1 LTP in Cacna1c (F) and Cacna1c+/+ slices (G). H Summary of EPSC amplitude change at 30–35 min shown in (F) and (G): no effect of genotype (LR(1) = 0.103, p = 0.748) or genotype × pathway interaction (LR(1) = 0.227, p = 0.633) on LTP. Pairwise Test vs Control for Cacna1c+/−: p = 0.0027, n = 10(7); Cacna1c+/+: p = 0.0011, n = 8(6). I Electrode placements (left) and TBP protocol (right) for LTP at TA-CA1 synapses. TBP induces homosynaptic TA-CA1 LTP in slices from Cacna1c (J) and Cacna1c animals (K). L Summary of changes in normalized EPSC amplitude at 30–35 min shown in (F) and (G): no effect of genotype (LR(1) = 0.0258, p = 0.8724) and no genotype × pathway interaction (LR(1) = 0.065, p = 0.798); contrast Test versus Control pathways, in Cacna1c: p = 0.0093, n = 8(7); Cacna1c: p = 0.014, n = 7(5). Plots show EPSC amplitude time-course in Test and Control pathways, normalized to 5 min average before LTP induction (arrowheads). Insets: 5 min average EPSC waveforms before (1, black) and 30–35 min after (2, red) LTP induction; scale bars: 50 pA, 50 ms. Sample sizes given as cells(animals—all males unless indicated). Data presented as means ± SEM. *p < 0.05, **p < 0.01 determined by two-way ordinal regression (cumulative link model) followed by analysis of deviance (ANODE) (colour figure online). To discern whether non-specific impairments of postsynaptic mechanisms caused the failure of SC-CA1 LTP in Cacna1c+/− animals, we tested an alternative LTP induction by pairing low-frequency synaptic stimulation with tonic postsynaptic depolarization (LFS-pairing, Fig. 2E). LFS-pairing generates NMDAR-dependent LTP without postsynaptic APs or L-VGCC contribution [45]. LFS-pairing induced robust SC-CA1 LTP in both genotypes (Fig. 2F–H), which was insensitive to L-VGCC antagonists but was blocked by L-689560 (Fig. S4D–F, H) confirming the dependency of LFS-pairing LTP on NMDARs but not L-VGCCs. In contrast, TA-CA1 synapses exhibited robust TBP-LTP in both genotypes (Fig. 2I–L) which was sensitive to L-VGCC block in wild-type slices (Fig. S4G, H). Paired-pulse facilitation was similar between genotypes (Fig. S5) indicating unaltered neurotransmitter release. These results show that Cacna1c hemizygosity selectively impairs forms of LTP that require L-VGCC activation during postsynaptic AP bursts, without affecting NMDAR-dependent mechanisms, at the SC-CA1 pathway.

Cacna1c CA1 pyramidal neurons have impaired spine Ca2+ signalling during postsynaptic spike bursts

Cacna1c CA1 pyramidal neurons had a small reduction in isradipine-sensitive whole-cell calcium currents (Fig. S6) measured using a voltage-ramp method [24] (Supplementary Methods). We hypothesized that the observed neurophysiological deficits arise from local alterations in CaV1.2 availability for processes such as AP repolarization and spine Ca2+ signalling, which we investigated next. Neurons from both genotypes had comparable passive membrane properties, AP threshold and rheobase current (Supplementary Table S1, Fig. S7A–E). However, somatic AP broadening during high-frequency (>40 Hz) firing was significantly reduced in Cacna1c+/− neurons compared to wild-type cells (Fig. S7F–I). Somatic AP broadening occurs normally during AP bursts, mediated by voltage- and Ca2+-sensitive K+ channel complexes [46, 47] which can associate CaV1.2 L-VGCCs [48, 49]. In Cacna1c+/+ neurons isradipine lowered somatic AP broadening to levels comparable to those in Cacna1c+/− neurons in the absence of drug (Fig. S7J, K). Therefore, low CaV1.2 dosage appears to alter Ca2+-sensitive spike repolarization during burst firing. AP broadening in CA1 pyramidal neurons is thought to facilitate dendritic backpropagation of somatic spikes [50] necessary for associative synaptic plasticity such as TBP-LTP [26, 44] and amplification of Ca2+ signals during AP bursts [47]. CaV1.2 L-VGCCs are expressed in dendrites and dendritic spines [51, 52], and are activated by backpropagated APs [26, 51]. The impaired AP broadening during burst firing in Cacna1c+/− neurons may impact plasticity induction by altering dendritic spine Ca2+ signals triggered by backpropagated APs. We tested this hypothesis by analyzing Ca2+ transients elicited with AP bursts (APCaTs) in spines of radial oblique dendrites (Figs. 3A, B and S8, Supplementary Tables S2 and S3). APCaTs attenuated with increasing distance from soma (Figs. 3C–E and S9). Compared to wild-type cells, the APCaTs in spines at 150–250 µm from soma in Cacna1c+/− neurons were consistently smaller (Fig. 3D, E) and scaled poorly with AP burst size (Figs. 3F, G and S10).
Fig. 3

Low Cacna1c dosage is correlated with a reduction of spine Ca2+ signals elicited by backpropagated action potentials in CA1 pyramidal cells.

A CA1 pyramidal neuron during spine Ca2+ imaging (Z-projected pseudo-colour image, Alexa Fluor 594 channel; white square: spine imaging region; e: recording electrode; scale: 50 µm). B Imaging of spine Ca2+ transients elicited by backpropagated action potentials (APCaTs). Top-to-bottom: imaging region in (A) with spines (s1, s2), parent dendrite (d1, d2) and line-scan trajectory (red); line-scan images, Alexa Fluor 594 (Alexa) and Fluo 5F (Fluo) channels, during five somatic APs (Vm); APCaTs during the 5 APs (grey: ΔF/A, change in fluorescence intensity in Fluo channel, relative to Alexa channel; black: double-exponential fit). Scales, vertical: 2 µm, 20 mV, 0.1 arbitrary units (a.u.); horizontal: 0.2 s. C Example APCAT waveforms elicited by 1–5 somatic AP (Vm) in spines within three distance zones. Scale: 20 mV, 0.02 a.u., 0.2 s. APCaTs have smaller amplitude (D) and time integral (E) in Cacna1c versus Cacna1c neurons (pairwise comparisons of 5 AP APCaTs, in distance zones (µm) <150: amplitude p = 0.0473, time integral p = 0.414; 150–250: both measures p < 0.0001; 250–400: both measures p < 0.0001). F, G Summation of APCaT amplitude (F) and time integral (G) with the number of APs is reduced in Cacna1c versus Cacna1c neurons (pairwise comparisons for APCaTs at 150–250 µm, for 2 AP: normalized amplitude p = 0.15, normalized time integral p < 0.0001, 3 AP: both measures p < 0.0001; 5 AP: both measures p < 0.0001). Data were expressed as means ± SEM. *p < 0.05, **p < 0.01 and ***p < 0.001 determined by two-way repeated measures ANOVA followed by Tukey adjustment of p values for contrasts. Statistical analysis results and sample sizes are given in Supplementary Table S2 and Fig. S8; all p values for pairwise comparisons are given in Supplementary Table S3 (colour figure online).

Low Cacna1c dosage is correlated with a reduction of spine Ca2+ signals elicited by backpropagated action potentials in CA1 pyramidal cells.

A CA1 pyramidal neuron during spine Ca2+ imaging (Z-projected pseudo-colour image, Alexa Fluor 594 channel; white square: spine imaging region; e: recording electrode; scale: 50 µm). B Imaging of spine Ca2+ transients elicited by backpropagated action potentials (APCaTs). Top-to-bottom: imaging region in (A) with spines (s1, s2), parent dendrite (d1, d2) and line-scan trajectory (red); line-scan images, Alexa Fluor 594 (Alexa) and Fluo 5F (Fluo) channels, during five somatic APs (Vm); APCaTs during the 5 APs (grey: ΔF/A, change in fluorescence intensity in Fluo channel, relative to Alexa channel; black: double-exponential fit). Scales, vertical: 2 µm, 20 mV, 0.1 arbitrary units (a.u.); horizontal: 0.2 s. C Example APCAT waveforms elicited by 1–5 somatic AP (Vm) in spines within three distance zones. Scale: 20 mV, 0.02 a.u., 0.2 s. APCaTs have smaller amplitude (D) and time integral (E) in Cacna1c versus Cacna1c neurons (pairwise comparisons of 5 AP APCaTs, in distance zones (µm) <150: amplitude p = 0.0473, time integral p = 0.414; 150–250: both measures p < 0.0001; 250–400: both measures p < 0.0001). F, G Summation of APCaT amplitude (F) and time integral (G) with the number of APs is reduced in Cacna1c versus Cacna1c neurons (pairwise comparisons for APCaTs at 150–250 µm, for 2 AP: normalized amplitude p = 0.15, normalized time integral p < 0.0001, 3 AP: both measures p < 0.0001; 5 AP: both measures p < 0.0001). Data were expressed as means ± SEM. *p < 0.05, **p < 0.01 and ***p < 0.001 determined by two-way repeated measures ANOVA followed by Tukey adjustment of p values for contrasts. Statistical analysis results and sample sizes are given in Supplementary Table S2 and Fig. S8; all p values for pairwise comparisons are given in Supplementary Table S3 (colour figure online). These results show that low Cacna1c dosage in CA1 pyramidal neurons alters AP-associated spine Ca2+ signalling at SC-CA1 synapses, which may underlie the observed selective deficit in synaptic plasticity.

Cacna1c animals have reduced Phase-Amplitude Coupling between theta and gamma oscillations of dorsal CA1 LFP

The establishment of neuronal ensembles involved in novel environment encoding depends on the synchronization of excitatory inputs in the CA1 subfield, facilitating synaptic plasticity [21, 53, 54]. To determine the impact of Cacna1c heterozygosity on dorsal CA1 network synchronization, we monitored the modulation of LFP gamma oscillations by the phase of LFP theta oscillations (theta–gamma Phase-Amplitude Coupling, PAC). Hippocampal theta–gamma PAC is a proposed mechanism for storage and recall of object and event representations [22, 55, 56]. The slow (~25–40 Hz) and fast (~ 65–140 Hz) gamma oscillations in dorsal CA1 reflect the synchronization between pyramidal neurons in CA1 with neurons in CA3 (via SC-CA1 pathway) and entorhinal cortex (EC) (via TA-CA1 pathway) [57]. To determine the changes in theta–gamma PAC during the exploration of a novel environment we recorded dorsal CA1 LFP oscillations in rats running along a track in a familiar, then a novel environment (Figs. 4A and S11A–C). This approach accounts for correlations of hippocampal theta and gamma rhythms and their coupling with movement [58-60]. In the familiar environment, animals from both genotypes had similar PAC across the gamma frequency spectrum (Fig. 4B, C, “Familiar” sub-panels) and power spectra of LFP oscillations in the 1–40 Hz range (Fig. S11D, E). Upon switching to novel environment, the PAC levels in Cacna1c+/+ were similar to the initial response to the subsequently familiar environment (Fig. 4B, C, “Novel” sub-panels). Cacna1c animals had significantly impaired theta–gamma PAC response (Fig. 4B, C) in the novel environment, unrelated to behavioural response to novelty (Fig. S12). Our results reveal a CA3–CA1 network mis-coupling in Cacna1c animals, which may further disrupt hippocampal encoding of contextual information and contribute to the observed LI deficit.
Fig. 4

Reduced theta-slow-gamma coupling in a novel environment in Cacna1c+/− rats.

A Local field potentials taken from runs on the familiar track. Top: Representative broadband LFP traces (0.1–475 Hz) taken from dorsal CA1 in a 5 s window while running. Bottom: 1 s expanded segment showing raw unfiltered LFP (top) and bandpass filtered theta (6–10 Hz), slow gamma (25–55 Hz) and fast gamma (60–140 Hz) (bottom). Phase-amplitude coupling measures the degree to which the amplitude envelope (blue traces shown for slow and fast gamma) is modulated by the phase signal (theta filtered LFP). Black: Cacna1c; red: Cacnac1; dashed vertical lines mark timings of theta cycle peaks. B Mean phase–amplitude coupling comodulograms taken from track runs on the familiar and novel track. Colour represents the modulation index (MI) depicting the degree of coupling between the phase of frequencies (1–20 Hz) on the x-axis and the amplitude of frequencies (1–200 Hz) on the y-axis. Differences between environments and genotypes are shown next to the mean plots as labelled (Cacna1c: n = 5; Cacna1c: n = 7). C Mean phase–amplitude coupling between theta (6–10 Hz) and slow gamma (25–55 Hz). Theta–slow gamma coupling was lower in Cacna1c rats than Cacna1c rats on the novel track (p = 0.0256) but not on the familiar track (p = 0.9184). Cacna1c: n = 5; Cacna1c: n = 7; Data presented as means ± SEM. *p < 0.05, Student’s t test (colour figure online).

Reduced theta-slow-gamma coupling in a novel environment in Cacna1c+/− rats.

A Local field potentials taken from runs on the familiar track. Top: Representative broadband LFP traces (0.1–475 Hz) taken from dorsal CA1 in a 5 s window while running. Bottom: 1 s expanded segment showing raw unfiltered LFP (top) and bandpass filtered theta (6–10 Hz), slow gamma (25–55 Hz) and fast gamma (60–140 Hz) (bottom). Phase-amplitude coupling measures the degree to which the amplitude envelope (blue traces shown for slow and fast gamma) is modulated by the phase signal (theta filtered LFP). Black: Cacna1c; red: Cacnac1; dashed vertical lines mark timings of theta cycle peaks. B Mean phase–amplitude coupling comodulograms taken from track runs on the familiar and novel track. Colour represents the modulation index (MI) depicting the degree of coupling between the phase of frequencies (1–20 Hz) on the x-axis and the amplitude of frequencies (1–200 Hz) on the y-axis. Differences between environments and genotypes are shown next to the mean plots as labelled (Cacna1c: n = 5; Cacna1c: n = 7). C Mean phase–amplitude coupling between theta (6–10 Hz) and slow gamma (25–55 Hz). Theta–slow gamma coupling was lower in Cacna1c rats than Cacna1c rats on the novel track (p = 0.0256) but not on the familiar track (p = 0.9184). Cacna1c: n = 5; Cacna1c: n = 7; Data presented as means ± SEM. *p < 0.05, Student’s t test (colour figure online).

A TrkB/TrkC agonist rescues synaptic plasticity and behavioural deficits in Cacna1c animals

We next investigated molecular changes associated with altered hippocampal synaptic plasticity and network activity in Cacna1c animals. The deficit in AP-elicited spine Ca2+ signals in Cacna1c rats may impact on Ca2+-dependent ERK signalling, which couples CaV1.2 L-VGCCs activation to synaptic plasticity [27, 28] and CREB-regulated gene expression for long-term memory [29, 30]. Phosphorylated ERK (pERK, Fig. 5A) and CREB (pCREB, Fig. 5B) immunoreactivities were significantly reduced in Cacna1c dorsal hippocampus. A separate cohort replicated these findings (Fig. S13A, C) without genotype effect on total ERK and CREB levels (Fig. S13B, D). We detected no differences in hippocampal morphology and cellular density between genotypes (Fig. S14). These results indicate impaired ERK- and CREB-mediated synapse-to-nucleus signalling in Cacna1c+/− rats, that may contribute to the observed behavioural and hippocampal dysfunctions. We tested this hypothesis by directly activating ERK signalling using a recently characterized small-molecule TrkB/TrkC neurotrophin receptor co-activator LM22B-10 with brain-derived neurotrophic factor (BDNF) mimetic properties including ERK activation in neurons [61]. Systemic administration of LM22B-10 in Cacna1c+/− rats (25 mg/kg i.p., yielding micromolar concentrations in the brain [61]) restored the baseline levels of pERK and pCREB 60 min after injection (Figs. 5A, B and S15) without significant effect in wild-type littermates. We next determined whether LM22B-10 could rescue hippocampal synaptic plasticity in Cacna1c+/− rats. LM22B-10 rescued TBP-LTP at SC-CA1 synapses in Cacna1c+/− slices, either during bath-application in vitro (Fig. 5C, G) or in slices prepared 60 min after intra-peritoneal administration (Fig. 5E, G), without effect in Cacna1c littermates (Fig. 5D, F, G). Thus, activation of TrkB/TrkC receptors with local or systemic administration of a BDNF mimetic drug bypasses CaV1.2 L-type VGCC signalling to rescue ERK signalling and associative hippocampal plasticity in Cacna1c+/− rats.
Fig. 5

The TrkB/TrkC receptor agonist LM22B-10 rescued dorsal hippocampal ERK-CREB signalling, synaptic plasticity, and LI of CFC in Cacna1c+/− rats.

Systemic administration of the TrkB/TrkC agonist LM22B-10 (25 mg/kg, i.p.) restored the baseline levels of pERK (A) and pCREB (B) in dorsal hippocampus of Cacna1c rats; pERK genotype × treatment: F(1,16) = 4.567, p = 0.048; genotype effect, vehicle-treated (Veh): F(1,16) = 12.866, p = 0.002; LM22B-10-treated: F(1,16) = 0.615, p = 0.444; pCREB genotype × treatment: F(1,17) = 5.239, p = 0.035; genotype effect, Veh: F(1,16) = 21.319, p = 0.000, and LM22B-10: F(1,16) = 2.485, p = 0.133. There was no significant treatment effect in Cacna1c animals (pERK: F(1,21) = 0.54, p = 0.47; pCREB: F(1,21) = 0.98, p = 0.33). Bars represent summary of immunopositive cell densities in CA1, CA3 and dentate gyrus (DG) of dorsal hippocampus, normalized to average Cacna1c values. Examples of immunoreactive sections are shown in Fig. S14. Animals were sacrificed 60 min after i.p. administration of drug or vehicle and processed for both ERK and CREB; sample sizes for Cacna1c: LM22B-10 n = 5, Veh n = 4; Cacna1c: LM22B-10 n = 6, Veh n = 5 (pERK) and n = 6 (pCREB). C–G LM22B-10 rescued SC-CA1 LTP induction with TBP in slices from Cacna1c rats, either during bath application (2 µM, C) or after i.p. bolus (25 mg/kg, E). LM22B-10 had no effect on TBP-induced SC-CA1 LTP in wild-type slices, either during bath application (D) or after i.p. bolus (F). Insets: 5 min average EPSC waveforms before (1, black) and 30–35 min after (2, red) LTP induction; scale bars: 50 pA, 50 ms. G Summary of change in normalized mean EPSC amplitude at 30–35 min after LTP in (C–F). Pairwise test vs control, C p = 0.034, n = 12(4); D p = 0.032, n = 7(4); E p = 0.044, n = 7(4); F p = 0.008, n = 7(5); sample sizes given as cells(animals). H Intrahippocampal infusion of LM22B-10 before context pre-exposure rescued LI of CFC in Cacna1c animals. Schematic: behavioural paradigm in Fig. S1 extended with memory retrieval trials in LI context (LTM3, LTM4), alternative context training (CFC B) and retrieval (LTM B). Arrowhead: bilateral infusion of 1 µl LM22B-10 (2 µM, n = 8) or vehicle (Veh, n = 6) in dorsal hippocampus 60 min before PE. The plot shows the freezing response in all sessions. I Summary of freezing response at LTM trials. The freezing responses in LM22B-10 and Veh groups were different (treatment × stage: F(5,60) = 5.205, p = 0.002). Compared to the vehicle group, LM22B-10 animals showed reduced freezing responses only in the LI context (between-subject contrasts vs Veh, LTM1: F(1,11) = 4.162, p = 0.033, LTM2: F(1,11) = 18.467, p = 0.0005, LTM3: F(1,11) = 9.602, p = 0.005, LTM4: F(1,11) = 6.886, p = 0.012, LTM B: F = 0.138, p = 0.358). All data are presented as means ± SEM. *p < 0.05, **p < 0.01 and ***p < 0.001, two-way repeated measures ANOVA then pairwise post-hoc comparison with Bonferroni correction (A, B, G, H) and two-way ordinal regression (ANODE) then Tukey-adjusted post-hoc comparisons (colour figure online).

The TrkB/TrkC receptor agonist LM22B-10 rescued dorsal hippocampal ERK-CREB signalling, synaptic plasticity, and LI of CFC in Cacna1c+/− rats.

Systemic administration of the TrkB/TrkC agonist LM22B-10 (25 mg/kg, i.p.) restored the baseline levels of pERK (A) and pCREB (B) in dorsal hippocampus of Cacna1c rats; pERK genotype × treatment: F(1,16) = 4.567, p = 0.048; genotype effect, vehicle-treated (Veh): F(1,16) = 12.866, p = 0.002; LM22B-10-treated: F(1,16) = 0.615, p = 0.444; pCREB genotype × treatment: F(1,17) = 5.239, p = 0.035; genotype effect, Veh: F(1,16) = 21.319, p = 0.000, and LM22B-10: F(1,16) = 2.485, p = 0.133. There was no significant treatment effect in Cacna1c animals (pERK: F(1,21) = 0.54, p = 0.47; pCREB: F(1,21) = 0.98, p = 0.33). Bars represent summary of immunopositive cell densities in CA1, CA3 and dentate gyrus (DG) of dorsal hippocampus, normalized to average Cacna1c values. Examples of immunoreactive sections are shown in Fig. S14. Animals were sacrificed 60 min after i.p. administration of drug or vehicle and processed for both ERK and CREB; sample sizes for Cacna1c: LM22B-10 n = 5, Veh n = 4; Cacna1c: LM22B-10 n = 6, Veh n = 5 (pERK) and n = 6 (pCREB). C–G LM22B-10 rescued SC-CA1 LTP induction with TBP in slices from Cacna1c rats, either during bath application (2 µM, C) or after i.p. bolus (25 mg/kg, E). LM22B-10 had no effect on TBP-induced SC-CA1 LTP in wild-type slices, either during bath application (D) or after i.p. bolus (F). Insets: 5 min average EPSC waveforms before (1, black) and 30–35 min after (2, red) LTP induction; scale bars: 50 pA, 50 ms. G Summary of change in normalized mean EPSC amplitude at 30–35 min after LTP in (C–F). Pairwise test vs control, C p = 0.034, n = 12(4); D p = 0.032, n = 7(4); E p = 0.044, n = 7(4); F p = 0.008, n = 7(5); sample sizes given as cells(animals). H Intrahippocampal infusion of LM22B-10 before context pre-exposure rescued LI of CFC in Cacna1c animals. Schematic: behavioural paradigm in Fig. S1 extended with memory retrieval trials in LI context (LTM3, LTM4), alternative context training (CFC B) and retrieval (LTM B). Arrowhead: bilateral infusion of 1 µl LM22B-10 (2 µM, n = 8) or vehicle (Veh, n = 6) in dorsal hippocampus 60 min before PE. The plot shows the freezing response in all sessions. I Summary of freezing response at LTM trials. The freezing responses in LM22B-10 and Veh groups were different (treatment × stage: F(5,60) = 5.205, p = 0.002). Compared to the vehicle group, LM22B-10 animals showed reduced freezing responses only in the LI context (between-subject contrasts vs Veh, LTM1: F(1,11) = 4.162, p = 0.033, LTM2: F(1,11) = 18.467, p = 0.0005, LTM3: F(1,11) = 9.602, p = 0.005, LTM4: F(1,11) = 6.886, p = 0.012, LTM B: F = 0.138, p = 0.358). All data are presented as means ± SEM. *p < 0.05, **p < 0.01 and ***p < 0.001, two-way repeated measures ANOVA then pairwise post-hoc comparison with Bonferroni correction (A, B, G, H) and two-way ordinal regression (ANODE) then Tukey-adjusted post-hoc comparisons (colour figure online). The reversal of molecular and synaptic plasticity deficits in Cacna1c+/− rats with LM22B-10 prompted us to investigate whether activation of hippocampal TrkB/TrkC receptors could rescue the observed deficit in LI of CFC. A single intra-dorsal hippocampal administration of LM22B-10 60 min before the pre-exposure stage of LI training rescued the LI of CFC in Cacna1c+/− animals tested 24 h, 7 days and 21 days after CFC training (Fig. 5G, H). To assess whether intrahippocampal infusion had non-specific confounding effects on hippocampal function, animals received a second CFC in a separate novel context (context B) in the absence of any infusion, 22 or 23 days later. In the novel context B, animals expressed equivalent levels of freezing responses to context and normal hippocampal-dependent CFC and fear memory (Fig. 5G, H). LM22B-10 infused rats showed intact and context-specific LI of CFC when returned to the original conditioned context at LTM4 (Fig. 5G, H). Therefore, intrahippocampal infusion of LM22B-10 rescued LI without deleterious effects on hippocampal function. In a separate cohort of Cacna1c+/− rats, intra-peritoneal injection of LM22B-10 throughout the LI procedure also rescued LI of CFC (Fig. S16). Together, these findings show that activation of the ERK signalling pathway in the dorsal hippocampus during LI pre-exposure is sufficient to rescue the behavioural deficits seen in Cacna1c+/− rats. This effect can be achieved with both intrahippocampal administration of LM22B-10 and with systemic dosing.

Discussion

Advances in psychiatric genomics have consistently revealed association of schizophrenia, bipolar disorder and related neurodevelopmental disorders with genetic variation in VGCCs and in particular CACNA1C. Understanding the impact of genetic variation in the associated loci is critical for gaining mechanistic insight into these conditions and development of new therapies. Psychotic symptoms pathognomonic of schizophrenia and frequent in bipolar disorder have been associated with altered learning about associations between environmental stimuli [18-20], leading to aberrant attribution of importance (or salience) to irrelevant events [36]. This aberrant learning can be objectivized by the LI procedure, which requires hippocampal and mesolimbic dopaminergic functional integrity [18, 37] and is affected in psychosis [17]. Consistent with impairments seen in psychotic patients, we found that low dosage of Cacna1c produced a marked deficit in contextual LI despite normal contextual fear conditioning. Our observations agree with previous studies of homozygous deletions of Cacna1c or Cacna1d (encoding the pore-forming subunits of CaV1.2 and CaV1.3 L-VGCCs, respectively) showing that CaV1.3, but not CaV1.2, is essential for acquisition of fear associations [35, 62]. Together with evidence from brain-specific knock-out studies [24, 63] our findings support a requirement for CaV1.2, but not CaV1.3, in context discrimination. The disruption of LI in wild-type animals and rescue in Cacna1c littermates by intrahippocampal drugs implicates the hippocampus as a major lesion site in our model. Therefore, hippocampal encoding of contextual information needed for LI may be particularly susceptible to alterations in Cacna1c dosage. Further studies are needed into potential upstream changes and the impact of this hippocampal dysfunction on mesolimbic dopamine signalling [16, 64] in our model. Formation of novel context representations in the hippocampus involves synaptic LTP at excitatory afferents from EC and CA3 area during theta-burst firing [53]. We hypothesized that the low CaV1.2 dosage in Cacna1c rats impacts on both LTP and the coordination of synaptic activity in CA1. Associative LTP is induced during theta-burst firing (TBP-LTP) by temporally coordinated pre- and postsynaptic neuronal activity and the activation of postsynaptic NMDARs and VGCCs [25, 26, 44]. In Cacna1c+/− animals, TBP-LTP was impaired at SC-CA1 pathway although SC-CA1 synapses are capable of L-VGCC-independent LTP. This distinction mitigates against spine abnormalities as principal cause for the plasticity deficit. To understand the causes of the SC-CA1 TBP-LTP deficit we investigated excitability and spine calcium signalling in Cacna1c+/− CA1 pyramidal neurons. Cacna1c+/− neurons had significantly reduced broadening of somatic APs during theta-burst-like firing, replicated in wild-type cells by L-VGCC block with isradipine, confirming a role for L-VGCCs. Consistent with weaker dendritic Ca2+ signals elicited by narrower APs [51] we observed inefficient summation of spine Ca2+ signals at SC-CA1 synapses during AP bursts in Cacna1c+/− neurons. Our findings reveal a mechanism by which Cacna1c hemizygosity causes inadequate AP-triggered spine Ca2+ signalling disrupting the pre- and postsynaptic spiking association necessary for LTP [26]. A necessary pharmacological dissection of the relative contributions of CaV1.2 and CaV1.3 in these processes depends on the advent of isoform-selective antagonists, which are not yet available [33]. In Cacna1c animals TBP-LTP was preserved at the other major excitatory input, TA-CA1. This dissociation suggests that Cacna1c hemizygosity does not affect L-VGCC-dependent mechanisms in distal dendrites, where local spiking is more important for LTP [25]. Our results suggest an impaired processing of conjunctive EC and CA3 inputs to CA1 leading to altered novel context representations in Cacna1c animals. Network synchronization in CA1 may contribute to the establishment of hippocampal memory traces by providing adequate temporal coordination between pre- and postsynaptic spiking [21]. PAC between CA1 theta and slow-gamma oscillations in Cacna1c rats was reduced specifically during exploration of a novel environment, indicating a mis-coupling between CA1 neurons and excitatory input from CA3 [55]. Theta–gamma PAC alterations across brain regions observed in animal models of psychosis [65] and schizophrenic patients [66], may reflect wider network deficits in psychoses. One behavioural consequence of low Cacna1c dosage is a contextual LI deficit. Nevertheless, Cacna1c rats are apparently able to form contextual fear memories. This suggests that the ability to form context representations or associative contextual memory—an event or non-event in the context—is altered but not absent in our model. The successful retrieval and behavioural expression of such memories depends on reactivation of firing activity in distinct sparse hippocampal neuronal ensembles or engrams formed during learning [67, 68]. Altered engram formation may impair engram indexing function [68, 69], which may normally contribute to retrieval of the context-no event memory during conditioning, or retrieval of a specific memory during recall. At molecular level, L-VGCC-mediated Ca2+ signalling imparts location and temporal specificity for excitation–transcription coupling and activation of ERK signalling [29, 30]. ERK is necessary for early [27, 28] and late, protein synthesis dependent, LTP and memory [70]. We found a markedly decreased activation of ERK and CREB in Cacna1c+/− hippocampi, despite unchanged hippocampal cytoarchitecture [3]. Taken together our results show that Cacna1c hemizygosity impairs hippocampal function and ERK signalling-mediated excitation–transcription coupling likely to result in behavioural deficits observed in Cacna1c animals. Our findings implicate constitutively dysregulated Cacna1c expression in psychiatric risk, in line with altered cognitive functions and synaptic plasticity following embryonic ablation of Cacna1c in glutamatergic neurons [71]. An important future aim is to determine with greater confidence the contribution of specific cell types to these phenotypes. Recent studies support the targeting of neurotrophin receptors using small-molecule BDNF mimetics as potential therapeutic strategy in neuropsychiatric and neurodegenerative disorders [72, 73]. We tested the effects of the small-molecule TrkB/TrkC co-activator LM22B-10 with BDNF mimetic activity in vivo [61]. In Cacna1c animals, direct application of LM22B-10 on hippocampal slices rescued synaptic plasticity, as predicted by ERK’s role in early-phase LTP [27, 28, 74]. Hippocampal infusion of LM22B-10 during context pre-exposure was sufficient to rescue LI, suggesting that context representations formed during pre-exposure are stable without requiring ongoing treatment. Systemic treatment with LM22B-10 rescued hippocampal molecular and plasticity changes and restored normal LI behaviour in Cacna1c+/− rats. Future work will focus on effects of LM22B-10 on network activity in vivo, not addressed in this study, and translational biomarkers as provided by brain imaging. In conclusion, by adopting a genomically informed approach to investigate pathological processes associated with genetic risk for neuropsychiatric disorders we show that Cacna1c hemizygosity impairs selective forms of associative learning, hippocampal synaptic plasticity, network synchronization, and ERK signalling-mediated excitation–transcription coupling. In addition, our work supports investigating the potential benefit of drugs targeting neurotrophin receptor signalling in psychiatric disorders. Supplementary information Supplementary Table S2 Supplementary Table S3
  70 in total

1.  Genetic variation in CACNA1C affects brain circuitries related to mental illness.

Authors:  Kristin L Bigos; Venkata S Mattay; Joseph H Callicott; Richard E Straub; Radhakrishna Vakkalanka; Bhaskar Kolachana; Thomas M Hyde; Barbara K Lipska; Joel E Kleinman; Daniel R Weinberger
Journal:  Arch Gen Psychiatry       Date:  2010-09

Review 2.  Special Article: Translational Science Update. Pharmacological Implications of Emerging Schizophrenia Genetics: Can the Bridge From 'Genomics' to 'Therapeutics' be Defined and Traversed?

Authors:  Rebecca Birnbaum; Daniel R Weinberger
Journal:  J Clin Psychopharmacol       Date:  2020 Jul/Aug       Impact factor: 3.153

3.  A polygenic burden of rare disruptive mutations in schizophrenia.

Authors:  Shaun M Purcell; Jennifer L Moran; Menachem Fromer; Douglas Ruderfer; Nadia Solovieff; Panos Roussos; Colm O'Dushlaine; Kimberly Chambert; Sarah E Bergen; Anna Kähler; Laramie Duncan; Eli Stahl; Giulio Genovese; Esperanza Fernández; Mark O Collins; Noboru H Komiyama; Jyoti S Choudhary; Patrik K E Magnusson; Eric Banks; Khalid Shakir; Kiran Garimella; Tim Fennell; Mark DePristo; Seth G N Grant; Stephen J Haggarty; Stacey Gabriel; Edward M Scolnick; Eric S Lander; Christina M Hultman; Patrick F Sullivan; Steven A McCarroll; Pamela Sklar
Journal:  Nature       Date:  2014-01-22       Impact factor: 49.962

4.  A role for noncoding variation in schizophrenia.

Authors:  Panos Roussos; Amanda C Mitchell; Georgios Voloudakis; John F Fullard; Venu M Pothula; Jonathan Tsang; Eli A Stahl; Anastasios Georgakopoulos; Douglas M Ruderfer; Alexander Charney; Yukinori Okada; Katherine A Siminovitch; Jane Worthington; Leonid Padyukov; Lars Klareskog; Peter K Gregersen; Robert M Plenge; Soumya Raychaudhuri; Menachem Fromer; Shaun M Purcell; Kristen J Brennand; Nikolaos K Robakis; Eric E Schadt; Schahram Akbarian; Pamela Sklar
Journal:  Cell Rep       Date:  2014-11-06       Impact factor: 9.423

5.  Functional implications of a psychiatric risk variant within CACNA1C in induced human neurons.

Authors:  T Yoshimizu; J Q Pan; A E Mungenast; J M Madison; S Su; J Ketterman; D Ongur; D McPhie; B Cohen; R Perlis; L-H Tsai
Journal:  Mol Psychiatry       Date:  2014-11-18       Impact factor: 15.992

6.  Functional Characterization of Schizophrenia-Associated Variation in CACNA1C.

Authors:  Nicole Eckart; Qifeng Song; Rebecca Yang; Ruihua Wang; Heng Zhu; Andrew S McCallion; Dimitrios Avramopoulos
Journal:  PLoS One       Date:  2016-06-08       Impact factor: 3.240

7.  Genome-wide association study identifies 30 loci associated with bipolar disorder.

Authors:  Eli A Stahl; Gerome Breen; Andreas J Forstner; Andrew McQuillin; Stephan Ripke; Vassily Trubetskoy; Manuel Mattheisen; Yunpeng Wang; Jonathan R I Coleman; Héléna A Gaspar; Christiaan A de Leeuw; Stacy Steinberg; Jennifer M Whitehead Pavlides; Maciej Trzaskowski; Enda M Byrne; Tune H Pers; Peter A Holmans; Alexander L Richards; Liam Abbott; Esben Agerbo; Huda Akil; Diego Albani; Ney Alliey-Rodriguez; Thomas D Als; Adebayo Anjorin; Verneri Antilla; Swapnil Awasthi; Judith A Badner; Marie Bækvad-Hansen; Jack D Barchas; Nicholas Bass; Michael Bauer; Richard Belliveau; Sarah E Bergen; Carsten Bøcker Pedersen; Erlend Bøen; Marco P Boks; James Boocock; Monika Budde; William Bunney; Margit Burmeister; Jonas Bybjerg-Grauholm; William Byerley; Miquel Casas; Felecia Cerrato; Pablo Cervantes; Kimberly Chambert; Alexander W Charney; Danfeng Chen; Claire Churchhouse; Toni-Kim Clarke; William Coryell; David W Craig; Cristiana Cruceanu; David Curtis; Piotr M Czerski; Anders M Dale; Simone de Jong; Franziska Degenhardt; Jurgen Del-Favero; J Raymond DePaulo; Srdjan Djurovic; Amanda L Dobbyn; Ashley Dumont; Torbjørn Elvsåshagen; Valentina Escott-Price; Chun Chieh Fan; Sascha B Fischer; Matthew Flickinger; Tatiana M Foroud; Liz Forty; Josef Frank; Christine Fraser; Nelson B Freimer; Louise Frisén; Katrin Gade; Diane Gage; Julie Garnham; Claudia Giambartolomei; Marianne Giørtz Pedersen; Jaqueline Goldstein; Scott D Gordon; Katherine Gordon-Smith; Elaine K Green; Melissa J Green; Tiffany A Greenwood; Jakob Grove; Weihua Guan; José Guzman-Parra; Marian L Hamshere; Martin Hautzinger; Urs Heilbronner; Stefan Herms; Maria Hipolito; Per Hoffmann; Dominic Holland; Laura Huckins; Stéphane Jamain; Jessica S Johnson; Anders Juréus; Radhika Kandaswamy; Robert Karlsson; James L Kennedy; Sarah Kittel-Schneider; James A Knowles; Manolis Kogevinas; Anna C Koller; Ralph Kupka; Catharina Lavebratt; Jacob Lawrence; William B Lawson; Markus Leber; Phil H Lee; Shawn E Levy; Jun Z Li; Chunyu Liu; Susanne Lucae; Anna Maaser; Donald J MacIntyre; Pamela B Mahon; Wolfgang Maier; Lina Martinsson; Steve McCarroll; Peter McGuffin; Melvin G McInnis; James D McKay; Helena Medeiros; Sarah E Medland; Fan Meng; Lili Milani; Grant W Montgomery; Derek W Morris; Thomas W Mühleisen; Niamh Mullins; Hoang Nguyen; Caroline M Nievergelt; Annelie Nordin Adolfsson; Evaristus A Nwulia; Claire O'Donovan; Loes M Olde Loohuis; Anil P S Ori; Lilijana Oruc; Urban Ösby; Roy H Perlis; Amy Perry; Andrea Pfennig; James B Potash; Shaun M Purcell; Eline J Regeer; Andreas Reif; Céline S Reinbold; John P Rice; Fabio Rivas; Margarita Rivera; Panos Roussos; Douglas M Ruderfer; Euijung Ryu; Cristina Sánchez-Mora; Alan F Schatzberg; William A Scheftner; Nicholas J Schork; Cynthia Shannon Weickert; Tatyana Shehktman; Paul D Shilling; Engilbert Sigurdsson; Claire Slaney; Olav B Smeland; Janet L Sobell; Christine Søholm Hansen; Anne T Spijker; David St Clair; Michael Steffens; John S Strauss; Fabian Streit; Jana Strohmaier; Szabolcs Szelinger; Robert C Thompson; Thorgeir E Thorgeirsson; Jens Treutlein; Helmut Vedder; Weiqing Wang; Stanley J Watson; Thomas W Weickert; Stephanie H Witt; Simon Xi; Wei Xu; Allan H Young; Peter Zandi; Peng Zhang; Sebastian Zöllner; Rolf Adolfsson; Ingrid Agartz; Martin Alda; Lena Backlund; Bernhard T Baune; Frank Bellivier; Wade H Berrettini; Joanna M Biernacka; Douglas H R Blackwood; Michael Boehnke; Anders D Børglum; Aiden Corvin; Nicholas Craddock; Mark J Daly; Udo Dannlowski; Tõnu Esko; Bruno Etain; Mark Frye; Janice M Fullerton; Elliot S Gershon; Michael Gill; Fernando Goes; Maria Grigoroiu-Serbanescu; Joanna Hauser; David M Hougaard; Christina M Hultman; Ian Jones; Lisa A Jones; René S Kahn; George Kirov; Mikael Landén; Marion Leboyer; Cathryn M Lewis; Qingqin S Li; Jolanta Lissowska; Nicholas G Martin; Fermin Mayoral; Susan L McElroy; Andrew M McIntosh; Francis J McMahon; Ingrid Melle; Andres Metspalu; Philip B Mitchell; Gunnar Morken; Ole Mors; Preben Bo Mortensen; Bertram Müller-Myhsok; Richard M Myers; Benjamin M Neale; Vishwajit Nimgaonkar; Merete Nordentoft; Markus M Nöthen; Michael C O'Donovan; Ketil J Oedegaard; Michael J Owen; Sara A Paciga; Carlos Pato; Michele T Pato; Danielle Posthuma; Josep Antoni Ramos-Quiroga; Marta Ribasés; Marcella Rietschel; Guy A Rouleau; Martin Schalling; Peter R Schofield; Thomas G Schulze; Alessandro Serretti; Jordan W Smoller; Hreinn Stefansson; Kari Stefansson; Eystein Stordal; Patrick F Sullivan; Gustavo Turecki; Arne E Vaaler; Eduard Vieta; John B Vincent; Thomas Werge; John I Nurnberger; Naomi R Wray; Arianna Di Florio; Howard J Edenberg; Sven Cichon; Roel A Ophoff; Laura J Scott; Ole A Andreassen; John Kelsoe; Pamela Sklar
Journal:  Nat Genet       Date:  2019-05-01       Impact factor: 38.330

8.  Profiling gene expression in the human dentate gyrus granule cell layer reveals insights into schizophrenia and its genetic risk.

Authors:  Andrew E Jaffe; Daniel J Hoeppner; Takeshi Saito; Lou Blanpain; Joy Ukaigwe; Emily E Burke; Leonardo Collado-Torres; Ran Tao; Katsunori Tajinda; Kristen R Maynard; Matthew N Tran; Keri Martinowich; Amy Deep-Soboslay; Joo Heon Shin; Joel E Kleinman; Daniel R Weinberger; Mitsuyuki Matsumoto; Thomas M Hyde
Journal:  Nat Neurosci       Date:  2020-03-16       Impact factor: 24.884

9.  Common schizophrenia alleles are enriched in mutation-intolerant genes and in regions under strong background selection.

Authors:  Antonio F Pardiñas; Peter Holmans; Andrew J Pocklington; Valentina Escott-Price; Stephan Ripke; Noa Carrera; Sophie E Legge; Sophie Bishop; Darren Cameron; Marian L Hamshere; Jun Han; Leon Hubbard; Amy Lynham; Kiran Mantripragada; Elliott Rees; James H MacCabe; Steven A McCarroll; Bernhard T Baune; Gerome Breen; Enda M Byrne; Udo Dannlowski; Thalia C Eley; Caroline Hayward; Nicholas G Martin; Andrew M McIntosh; Robert Plomin; David J Porteous; Naomi R Wray; Armando Caballero; Daniel H Geschwind; Laura M Huckins; Douglas M Ruderfer; Enrique Santiago; Pamela Sklar; Eli A Stahl; Hyejung Won; Esben Agerbo; Thomas D Als; Ole A Andreassen; Marie Bækvad-Hansen; Preben Bo Mortensen; Carsten Bøcker Pedersen; Anders D Børglum; Jonas Bybjerg-Grauholm; Srdjan Djurovic; Naser Durmishi; Marianne Giørtz Pedersen; Vera Golimbet; Jakob Grove; David M Hougaard; Manuel Mattheisen; Espen Molden; Ole Mors; Merete Nordentoft; Milica Pejovic-Milovancevic; Engilbert Sigurdsson; Teimuraz Silagadze; Christine Søholm Hansen; Kari Stefansson; Hreinn Stefansson; Stacy Steinberg; Sarah Tosato; Thomas Werge; David A Collier; Dan Rujescu; George Kirov; Michael J Owen; Michael C O'Donovan; James T R Walters
Journal:  Nat Genet       Date:  2018-02-26       Impact factor: 38.330

10.  Evidence for 28 genetic disorders discovered by combining healthcare and research data.

Authors:  Joanna Kaplanis; Kaitlin E Samocha; Laurens Wiel; Zhancheng Zhang; Kevin J Arvai; Ruth Y Eberhardt; Giuseppe Gallone; Stefan H Lelieveld; Hilary C Martin; Jeremy F McRae; Patrick J Short; Rebecca I Torene; Elke de Boer; Petr Danecek; Eugene J Gardner; Ni Huang; Jenny Lord; Iñigo Martincorena; Rolph Pfundt; Margot R F Reijnders; Alison Yeung; Helger G Yntema; Lisenka E L M Vissers; Jane Juusola; Caroline F Wright; Han G Brunner; Helen V Firth; David R FitzPatrick; Jeffrey C Barrett; Matthew E Hurles; Christian Gilissen; Kyle Retterer
Journal:  Nature       Date:  2020-10-14       Impact factor: 49.962

View more
  4 in total

1.  BDNF Levels According to Variations in the CACNA1C Gene: Sex-Based Disparity.

Authors:  Clarissa Ribeiro Bastos; Janaina Xavier; Laísa Camerini; Samantha Seibt Dewes; Fernanda Pedrotti Moreira; Carolina David Wiener; Karen Jansen; Manuella Pinto Kaster; Luciano Dias de Mattos Souza; Ricardo Azevedo da Silva; Jean Pierre Oses; Luis Valmor Portela; Diogo Rizzato Lara; Luciana Tovo-Rodrigues; Gabriele Ghisleni
Journal:  Cell Mol Neurobiol       Date:  2022-02-06       Impact factor: 5.046

Review 2.  Schizophrenia Genomics: Convergence on Synaptic Development, Adult Synaptic Plasticity, or Both?

Authors:  Jeremy Hall; Nicholas J Bray
Journal:  Biol Psychiatry       Date:  2021-10-29       Impact factor: 13.382

Review 3.  Social Behavior and Ultrasonic Vocalizations in a Genetic Rat Model Haploinsufficient for the Cross-Disorder Risk Gene Cacna1c.

Authors:  Markus Wöhr; Theresa M Kisko; Rainer K W Schwarting
Journal:  Brain Sci       Date:  2021-05-29

4.  Reduced expression of the psychiatric risk gene DLG2 (PSD93) impairs hippocampal synaptic integration and plasticity.

Authors:  Simonas Griesius; Cian O'Donnell; Sophie Waldron; Kerrie L Thomas; Dominic M Dwyer; Lawrence S Wilkinson; Jeremy Hall; Emma S J Robinson; Jack R Mellor
Journal:  Neuropsychopharmacology       Date:  2022-02-03       Impact factor: 8.294

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.